Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
This creates negative suction pressure by holding the tongue in a forward position and increasing the airway space behind the tongue. Hybrid devices combine mandibular advancement with the tongue restraint. These devices have been used for snoring and obstructive sleep apnea. Tongue retaining devices have not been well-received as a therapy choice since they are invasive, and the acclimation period is long. The devices have shown high success rates for therapy. Soft-palate lifters are devices that lift the soft palate. They are useful for people who have weak muscles in the region. Evidence to support oral appliances/functional orthopedic appliances in children is insufficient, with very low evidence of effect. However, the oral appliances/functional orthopedic appliances may be considered in specified cases as an auxiliary in the treatment of children with craniofacial anomalies, which are risk factors for apnea.
== Adverse effects == In clinical trials, the most common adverse event was nausea (31%). Other adverse events (≥5% of patients) included diarrhea (13%), headache (13%), abdominal distension (5%), abdominal pain (5%), flatulence (6%), sinusitis (5%), vomiting (5%), and fecal incontinence (1%). The FDA lists the following: For subjects with chronic idiopathic constipation taking Amitiza:
viticella) and its cultivars). Montana Group: Cultivars belonging to, or derived from, species classified in section Montanae (Schneider) Grey-Wilson such as C. chrysocoma, C. montana, C. spooneri. Tangutica Group: Cultivars with at least one parent belonging to, or derived from, species classified in section Meclatis (Spach) Baill., such as C. intricata, C. ladakhiana, C. orientalis, C. serratifolia, C. tangutica, C. tibetana. This Group has also been known as the Orientalis Group. Texensis Group: Cultivars derived from C. texensis crossed with representatives from either of the Large-flowered Groups. Viorna Group: Cultivars with at least one parent belonging to, or derived from, species classified in section Viorna A. Gray, such as C. crispa, C. fusca, C. ianthina, C. pitcheri, C. reticulata, C. texensis, C. viorna. Cultivars assigned to Texensis Group, and cultivars with C. integrifolia in their parentage, are excluded. Vitalba Group: Cultivars with at least one parent belonging to, or derived from, species classified in section Clematis L., such as C. ligusticifolia, C. potaninii, C. vitalba, C. virginiana. Viticella Group: Cultivars with at least one parent mainly derived from C. viticella. Excludes hybrids between C. integrifolia and C. viticella: see Integrifolia Group. Large-flowered Division: Flowers (5–)10–22(–29) cm across, usually flat. Early Large-flowered Group: Comprises the former Patens Group and Fortunei Group. Cultivars of the Patens Group were derived mainly from C. patens, either directly or indirectly.
== Corporate management == The LLNL director reports to the Lawrence Livermore National Security, LLC (LLNS) board of governors, a group of key scientific, academic, national security and business leaders from the LLNS partner companies that jointly own and control LLNS. The LLNS board of governors has a total of 16 positions, with six of these governors constituting an executive committee. All decisions of the board are made by the governors on the executive committee. The other governors are advisory to the executive committee and do not have voting rights. The University of California is entitled to appoint three governors to the executive committee, including the chair. Bechtel is also entitled to appoint three governors to the executive committee, including the vice chair. One of the Bechtel governors must be a representative of Babcock & Wilcox (B&W) or the Washington Division of URS Corporation (URS), who is nominated jointly by B&W and URS each year, and who must be approved and appointed by Bechtel. The executive committee has a seventh governor who is appointed by Battelle; they are non-voting and advisory to the executive committee. The remaining board positions are known as independent governors (also referred to as outside governors), and are selected from among individuals, preferably of national stature, and can not be employees or officers of the partner companies. The University of California-appointed chair has tie-breaking authority over most decisions of the executive committee.
From 2011, new cars should have brake assist system in the EU, according to The Pedestrian Protection Regulation (EC) 78/2009. Starting in 2012, all cars under 10,000 lbs. sold in the US are required to have Electronic Stability Control. In 2014, ESP (Electronic Stability Program) and TPMS became mandatory in the European Union, with also the driver seat belt reminder and the ISOFIX system, under General Safety Regulation (EC) No 661/2009. In 2015, recognizing that safer roads are a shared responsibility, Together for Safer Roads (TSR) was formally launched to align the private sector's road safety efforts with the United Nations Decade of Action for Road Safety. In 2016 and 2017, ABS became mandatory on motorcycles in the EU. In 2018, eCall became mandatory in the EU, and reverse camera in the US. In 2019, the EU legislated to revise the General Safety Regulation (GSR), the revision includes the following automotive safety features:
Sources: en.wikipedia.org
Plant breeding started with sedentary agriculture and particularly the domestication of the first agricultural plants, a practice which is estimated to date back 9,000 to 11,000 years. Initially early farmers simply selected food plants with particular desirable characteristics, and employed these as progenitors for subsequent generations, resulting in an accumulation of valuable traits over time. Grafting technology had been practiced in China before 2000 BCE. By 500 BCE grafting was well established and practiced. Gregor Mendel (1822–84) is considered the "father of genetics". His experiments with plant hybridization led to his establishing laws of inheritance. Genetics stimulated research to improve crop production through plant breeding. Selective breeding played a crucial role in the Green Revolution of the 20th century. Modern plant breeding is applied genetics, but its scientific basis is broader, covering molecular biology, cytology, systematics, physiology, pathology, entomology, chemistry, and statistics (biometrics). It has also developed its own technology.
The National Institute for Health and Clinical Excellence (NICE), UK released updated diabetes recommendations on 30 May 2008, which recommend that self-monitoring of plasma glucose levels for people with newly diagnosed type 2 diabetes must be integrated into a structured self-management education process. The recommendations have been updated in August 2015 for children and young adults with type 1 diabetes. The American Diabetes Association (ADA), which produces guidelines for diabetes care and clinical practice recommendations, recently updated its "Standards of Medical Care" in January 2019 to acknowledge that routine self-monitoring of blood glucose in people who are not using insulin is of limited additional clinical benefit. A randomized controlled trial evaluated once-daily self-monitoring that included tailored patient messaging and did not show that this strategy led to significant changes in A1C after a year. Media related to Blood glucose monitoring at Wikimedia Commons
=== Controls === Nearly all VR games are played from a first-person perspective to take advantage of the level of immersion created by the headset. Player input, which includes the motion of their head, hands, and body and any controller buttons or triggers they depress, are translated into actions within the game. Most commonly, the player's view of the game's environment will track with how they move their hand, and they will be shown virtual hands to guide them how to interact with the environment, with VR translating the player's motions one-to-one with the virtual appendages. While games can be controlled through traditional controls such as KBM or a standard console controller, these interfaces break the level of immersion, and instead, more specialized controllers are used, typically designed to fit naturally into a player's hand.
D-Phenylalanine (DPA, D-Phe), sold under the brand names Deprenon, Sabiben, and Sabiden, is an enantiomer of phenylalanine which is described as an antidepressant and is marketed as a prescription drug for medical use in Argentina. The medication has been marketed since at least the 1970s and continued to be available by the 2000s. D-Phenylalanine has been found to act as an enkephalinase inhibitor, an inhibitor of enkephalinase enzymes that break down endogenous opioid peptides called enkephalins. It has been found to produce anti-inflammatory, analgesic, and anti-craving effects in animal studies.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。